

# Andrei Thomas-Tikhonenko

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3707095/publications.pdf>

Version: 2024-02-01

82  
papers

8,454  
citations

94381

37  
h-index

64755

79  
g-index

94  
all docs

94  
docs citations

94  
times ranked

15058  
citing authors

#	ARTICLE	IF	CITATIONS
1	Widespread microRNA repression by Myc contributes to tumorigenesis. <i>Nature Genetics</i> , 2008, 40, 43-50.	9.4	1,203
2	Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. <i>Nature Genetics</i> , 2006, 38, 1060-1065.	9.4	1,000
3	Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , 2015, 5, 1282-1295.	7.7	997
4	Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. <i>Journal of Clinical Investigation</i> , 2007, 117, 326-336.	3.9	983
5	Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3384-3389.	3.3	355
6	ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. <i>Journal of Clinical Investigation</i> , 2012, 122, 4621-4634.	3.9	336
7	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF- $\beta$ Pathway in Neuroblastoma. <i>Molecular Cell</i> , 2010, 40, 762-773.	4.5	279
8	The Myc-miR-17-92 Axis Blunts TGF- $\beta$ Signaling and Production of Multiple TGF- $\beta$ -Dependent Antiangiogenic Factors. <i>Cancer Research</i> , 2010, 70, 8233-8246.	0.4	248
9	Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity. <i>Molecular and Cellular Biology</i> , 2004, 24, 8541-8555.	1.1	227
10	Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis. <i>Molecular and Cellular Biology</i> , 2006, 26, 2373-2386.	1.1	210
11	CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. <i>Blood Advances</i> , 2019, 3, 3539-3549.	2.5	145
12	p53-Responsive miR-194 Inhibits Thrombospondin-1 and Promotes Angiogenesis in Colon Cancers. <i>Cancer Research</i> , 2011, 71, 7490-7501.	0.4	144
13	B cell-specific loss of histone 3 lysine 9 methylation in the VH locus depends on Pax5. <i>Nature Immunology</i> , 2004, 5, 853-861.	7.0	113
14	Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 13968-13973.	3.3	111
15	Oncogenic BRAF regulates $\beta$ -Trcp expression and NF- $\kappa$ B activity in human melanoma cells. <i>Oncogene</i> , 2007, 26, 1954-1958.	2.6	94
16	Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas. <i>Journal of the National Cancer Institute</i> , 2009, 101, 663-677.	3.0	87
17	CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. <i>Journal of Clinical Investigation</i> , 2012, 122, 2257-2266.	3.9	87
18	Viral Myc Oncoproteins in Infected Fibroblasts Down-modulate Thrombospondin-1, a Possible Tumor Suppressor Gene. <i>Journal of Biological Chemistry</i> , 1996, 271, 30741-30747.	1.6	80

#	ARTICLE	IF	CITATIONS
19	Role of GLI2 Transcription Factor in Growth and Tumorigenicity of Prostate Cells. <i>Cancer Research</i> , 2007, 67, 10642-10646.	0.4	78
20	Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E11-E13.	2.0	78
21	Activation of the Myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA. <i>Nucleic Acids Research</i> , 2000, 28, 2268-2275.	6.5	76
22	Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. <i>Oncogene</i> , 2011, 30, 2587-2594.	2.6	73
23	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. <i>Blood</i> , 2013, 122, 4220-4229.	0.6	70
24	Myc-Transformed Epithelial Cells Down-Regulate Clusterin, Which Inhibits Their Growth in Vitro and Carcinogenesis in Vivo. <i>Cancer Research</i> , 2004, 64, 3126-3136.	0.4	68
25	Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis. <i>Journal of Immunology</i> , 2001, 166, 5878-5881.	0.4	65
26	Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. <i>Leukemia</i> , 2020, 34, 1202-1207.	3.3	61
27	Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. <i>Blood</i> , 2003, 101, 1950-1955.	0.6	58
28	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. <i>Nature</i> , 2020, 588, 491-497.	13.7	57
29	CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	55
30	c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. <i>Cancer Biology and Therapy</i> , 2008, 7, 1758-1764.	1.5	54
31	Shielding the messenger (RNA): microRNA-based anticancer therapies. , 2011, 131, 18-32.		52
32	A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. <i>Oncogene</i> , 2002, 21, 1922-1927.	2.6	51
33	Targeting $\beta$ -Transducin Repeat-Containing Protein E3 Ubiquitin Ligase Augments the Effects of Antitumor Drugs on Breast Cancer Cells. <i>Cancer Research</i> , 2005, 65, 1904-1908.	0.4	51
34	MYC and the Art of MicroRNA Maintenance. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a014175-a014175.	2.9	51
35	Functional Validation of Genes Implicated in Lymphomagenesis: An In Vivo Selection Assay Using a Myc-Induced B-Cell Tumor. <i>Annals of the New York Academy of Sciences</i> , 2005, 1059, 145-159.	1.8	45
36	Targeting of TGF $\beta$ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. <i>Rna</i> , 2013, 19, 177-190.	1.6	45

#	ARTICLE	IF	CITATIONS
37	Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2018, 93, E352-E355.	2.0	44
38	Regulation of <i>CLU</i> Gene Expression by Oncogenes and Epigenetic Factors. <i>Advances in Cancer Research</i> , 2009, 105, 115-132.	1.9	40
39	Aberrant splicing in B-cell acute lymphoblastic leukemia. <i>Nucleic Acids Research</i> , 2018, 46, 11357-11369.	6.5	39
40	miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis. <i>Annals of Hematology</i> , 2016, 95, 881-891.	0.8	37
41	B cell activator <i>PAX5</i> promotes lymphomagenesis through stimulation of B cell receptor signaling. <i>Journal of Clinical Investigation</i> , 2007, 117, 2602-2610.	3.9	37
42	Infection and cancer: the common vein. <i>Cytokine and Growth Factor Reviews</i> , 2003, 14, 67-77.	3.2	31
43	Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. <i>Blood Cancer Discovery</i> , 2022, 3, 103-115.	2.6	31
44	Inactivation of <i>Myc</i> in Murine Two-Hit B lymphomas Causes Dormancy with Elevated Levels of Interleukin 10 Receptor and CD20: Implications for Adjuvant Therapies. <i>Cancer Research</i> , 2005, 65, 5454-5461.	0.4	29
45	<i>p53</i> status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. <i>Blood</i> , 2007, 109, 4936-4943.	0.6	29
46	Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. <i>Cancer Biology and Therapy</i> , 2007, 6, 1433-1437.	1.5	24
47	Transient stabilization, rather than inhibition, of <i>MYC</i> amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. <i>Leukemia</i> , 2019, 33, 2429-2441.	3.3	24
48	Escape From ALL-CARTaz. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 217-222.	1.0	20
49	Direct long-read RNA sequencing identifies a subset of questionable exons likely arising from reverse transcription artifacts. <i>Genome Biology</i> , 2021, 22, 190.	3.8	20
50	<i>gag</i> as well as <i>myc</i> sequences contribute to the transforming phenotype of the avian retrovirus FH3. <i>Journal of Virology</i> , 1992, 66, 946-955.	1.5	20
51	Inhibition of the Single Downstream Target <i>BAG1</i> Activates the Latent Apoptotic Potential of <i>MYC</i> . <i>Molecular and Cellular Biology</i> , 2011, 31, 5037-5045.	1.1	18
52	An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. <i>Cancer Biology and Therapy</i> , 2003, 2, 687-93.	1.5	17
53	The long reach of noncoding RNAs. <i>Nature Genetics</i> , 2011, 43, 616-617.	9.4	16
54	Masking Epistasis Between <i>MYC</i> and <i>TGF-<math>\beta</math>2</i> Pathways in Antiangiogenesis-Mediated Colon Cancer Suppression. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju043.	3.0	15

#	ARTICLE	IF	CITATIONS
55	RNA-binding proteins of COSMIC importance in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
56	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. <i>Nature Communications</i> , 2022, 13, 2228.	5.8	14
57	MOCCASIN: a method for correcting for known and unknown confounders in RNA splicing analysis. <i>Nature Communications</i> , 2021, 12, 3353.	5.8	12
58	Tilting MYC toward cancer cell death. <i>Trends in Cancer</i> , 2021, 7, 982-994.	3.8	12
59	B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages. <i>Experimental Cell Research</i> , 2007, 313, 331-340.	1.2	11
60	Identifying common transcriptome signatures of cancer by interpreting deep learning models. <i>Genome Biology</i> , 2022, 23, 117.	3.8	11
61	MYC Hyperactivates Wnt Signaling in <i>APC</i> / <i>CTNNB1</i> -Mutated Colorectal Cancer Cells through miR-92a-Dependent Repression of <i>DKK3</i> . <i>Molecular Cancer Research</i> , 2021, 19, 2003-2014.	1.5	9
62	Intratumoral delivery of an interferon gamma retrovirus-producing cells inhibits growth of a murine melanoma by a non-immune mechanism. <i>Cancer Letters</i> , 2001, 173, 145-154.	3.2	8
63	Epigenetic Histone Modifications Do Not Control Ig $\lambda$ Locus Contraction and Intranuclear Localization in Cells with Dual B Cell-Macrophage Potential. <i>Journal of Immunology</i> , 2006, 177, 6165-6171.	0.4	7
64	PAX5 and B-cell neoplasms: transformation through presentation. <i>Future Oncology</i> , 2008, 4, 5-9.	1.1	7
65	Avian endogenous provirus (ev-3) env gene sequencing: Implication for pathogenic retrovirus origination. <i>Virus Genes</i> , 1990, 3, 251-258.	0.7	6
66	Infection & Neoplastic Growth 101. <i>Cancer Treatment and Research</i> , 2006, , 167-197.	0.2	6
67	Distribution of mouse mammary tumor virus-related sequences does not correlate with the taxonomic position of their hosts. <i>Virus Genes</i> , 1990, 4, 85-92.	0.7	4
68	Long terminal repeats of dwarf hamster endogenous retrovirus are highly diverged and do not maintain efficient transcription. <i>Virology</i> , 1991, 181, 367-370.	1.1	4
69	Kit-activating mutations in AML: Lessons from PU.1-induced murine erythroleukemia. <i>Cancer Biology and Therapy</i> , 2006, 5, 579-581.	1.5	4
70	Colorectal Cancer-Associated Smad4 R361 Hotspot Mutations Boost Wnt/ $\beta$ -Catenin Signaling through Enhanced Smad4-LEF1 Binding. <i>Molecular Cancer Research</i> , 2021, 19, 823-833.	1.5	4
71	Molecular cloning and primary structure analysis of the mouse mammary tumor virus-related element from dwarf hamster genome. <i>Virus Genes</i> , 1990, 3, 259-261.	0.7	3
72	Whence Thrombospondin?. <i>Cancer Biology and Therapy</i> , 2004, 3, 406-407.	1.5	3

#	ARTICLE	IF	CITATIONS
73	Regulation of CD19 Exon 2 Inclusion in B-Lymphoid Cells By Splicing Factors and Epigenetic Marks. Blood, 2015, 126, 2425-2425.	0.6	3
74	The Importance of CD19 Exon 2 for Surface Localization: Closing the Ig-like Loop. Blood, 2015, 126, 3433-3433.	0.6	3
75	Exons of Leukemia Suppressor Genes: Creative Assembly Required. Trends in Cancer, 2018, 4, 796-798.	3.8	2
76	Pipeline for Discovering Neoepitopes Generated By Alternative Splicing in B-ALL. Blood, 2019, 134, 1342-1342.	0.6	2
77	Aiding and ABTâ€™ing treatment for glioblastoma. Cancer Biology and Therapy, 2007, 6, 802-804.	1.5	1
78	Myc and Control of Tumor Neovascularization. , 2010, , 167-187.		1
79	Poisoning the Messengers: Could Tumor Endothelial Cells Acquire Drug Resistance. Cancer Biology and Therapy, 2002, 1, 266-267.	1.5	0
80	Abstract B33: Transient upregulation of Myc with GSK3-Î² inhibitors in B-cell lymphomas enhances p53-independent apoptotic responses to chemotherapy. , 2015, , .		0
81	The Impact of Immunotherapy on Tumor Evolution. Blood, 2018, 132, SCI-18-SCI-18.	0.6	0
82	Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation. Blood, 2021, 138, 868-868.	0.6	0